<DOC>
	<DOC>NCT00740831</DOC>
	<brief_summary>This trial will assess the efficacy and safety of PGL4001 versus GnRH agonist, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.</brief_summary>
	<brief_title>PGL4001 Versus GnRH-agonist in Uterine Myomas</brief_title>
	<detailed_description />
	<mesh_term>Myoma</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Be a premenopausal woman between 18 and 50 years inclusive. Have excessive uterine bleeding due to myoma Have a myomatous uterus with at least one myoma of ≥ 3 cm diameter in size Be eligible for one surgical procedure: e.g. hysterectomy, myomectomy or others. If of childbearing potential the subject must be practicing a nonhormonal method of contraception. Have a Body Mass Index (BMI) ≥ 18 and ≤ 40. Has a history of or current uterine, cervical, ovarian or breast cancer. Has a history of or current endometrium atypical hyperplasia or adenocarcinoma. Has a known severe coagulation disorder. Has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM) or a GnRHagonist. Has a history of or known current osteoporosis. Has abnormal hepatic function at study entry. Has a positive pregnancy test at baseline or is nursing or planning a pregnancy during the course of the study. Has a current (within twelve months) problem with alcohol or drug abuse. Is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Uterine Myomas</keyword>
</DOC>